蛋白质组学在睾丸癌生物标志物鉴定中的应用——综述
Proteomics for the Identification of Biomarkers in Testicular Cancer-Review.
作者信息
Milardi Domenico, Grande Giuseppe, Vincenzoni Federica, Pierconti Francesco, Pontecorvi Alfredo
机构信息
International Scientific Institute "Paul VI", Rome, Italy.
Division of Endocrinology, Fondazione Policlinico'A. Gemelli' IRCCS, Rome, Italy.
出版信息
Front Endocrinol (Lausanne). 2019 Jul 12;10:462. doi: 10.3389/fendo.2019.00462. eCollection 2019.
A large number of biomarkers have been proposed for the diagnosis of testicular cancer, representing putative molecular targets for anticancer treatments. However, no conclusive data have been provided. Proteomics represents a research field recently developed. It evaluates the large-scale analysis of the full protein components of a single cell, of a specific tissue, or of biological fluids. In the last decades, proteomics has been applied in clinical fields, thanks to modern technology and new bioinformatic tools, to identify novel molecular markers of diseases. The aim of this review is to argue the findings of recent studies in the discoveries of putative prognostic and diagnostic markers of testis cancer by proteomic techniques. We present here a panel of proteins identified by proteomics which might be used after validation for early detection and the prognostic evaluation of testicular tumors. In addition, the molecular mechanisms revealed by these proteomic studies might also guide the development of novel treatments in future.
大量生物标志物已被提出用于睾丸癌的诊断，它们代表了抗癌治疗的潜在分子靶点。然而，尚未提供确凿的数据。蛋白质组学是最近发展起来的一个研究领域。它评估对单个细胞、特定组织或生物体液中全部蛋白质成分的大规模分析。在过去几十年中，由于现代技术和新的生物信息学工具，蛋白质组学已应用于临床领域，以识别疾病的新型分子标志物。本综述的目的是讨论蛋白质组学技术在睾丸癌潜在预后和诊断标志物发现方面的最新研究结果。我们在此展示一组通过蛋白质组学鉴定的蛋白质，这些蛋白质在经过验证后可能用于睾丸肿瘤的早期检测和预后评估。此外，这些蛋白质组学研究揭示的分子机制也可能在未来指导新型治疗方法的开发。
Zotero 插件